Patents by Inventor Veronica Juan

Veronica Juan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-TIGIT antibodies
    Patent number: 11958902
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: April 16, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY
    Publication number: 20240002535
    Abstract: Arginase 1 binders that inhibit activity of hArg1, which comprise humanized anti-human Arginase 1 (hArg1) antibodies and antigen-binding fragments thereof obtained from mouse monoclonal antibodies comprising mouse VH and VL, are described. These Arginase 1 binders present an alternative mechanism for inhibiting hArg1 activity and highlight the ability to utilize binders as probes in the discovery and development of peptide and small molecule inhibitors for enzymes in general.
    Type: Application
    Filed: November 22, 2021
    Publication date: January 4, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Marc Andre Bailly, Kalyan Chakravarthy, Ghassan Najib Fayad, Laurence Fayadat-Dilman, Veronica Juan, Esther Kofman, Masahisa Handa, Jennifer E. O'Neil, Rachel Lynn Palte, Giovanna Scapin, Shahriar Shane Taremi
  • ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY
    Publication number: 20240002533
    Abstract: Arginase 1 binders comprising human antibodies and antigen-binding fragments thereof that inhibit the activity of human Arginase 1 (hArg1) are described. These Arginase 1 binders present an alternative mechanism for inhibiting hArg1 activity and highlight the ability to utilize binders as probes in the discovery and development of peptide and small molecule inhibitors for enzymes in general.
    Type: Application
    Filed: November 22, 2021
    Publication date: January 4, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Marc Andre Bailly, Kalyan Chakravarthy, Ghassan Najib Fayad, Laurence Fayadat-Dilman, Veronica Juan, Esther Kofman, Heping Lin, Jennifer E. O'Neil, Rachel Lynn Palte, Giovanna Scapin, Hussam Hisham Shaheen, Tao Wang
  • ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BICPECIFIC ANTIBODIES
    Publication number: 20220251194
    Abstract: Provided herein are treatments of conditions ameliorated by counteracting tumor mediated immune suppression. More specifically, provided herein are anti-PD-1/LAG-3/TIGIT trispecific antibodies, anti-PD-1/LAG3 bispecific antibodies, anti-LAG3 antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: July 28, 2020
    Publication date: August 11, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Laurence Fayadat-Dilman, Veronica Juan, Robert A. Kastelein
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220033497
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: February 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220025042
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220025043
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220010011
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 13, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF
    Publication number: 20220010010
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 13, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
    Publication number: 20210371530
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: July 23, 2021
    Publication date: December 2, 2021
    Inventors: Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
  • ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
    Publication number: 20210363256
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 25, 2021
    Inventors: Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
  • Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
    Patent number: 11111297
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: September 7, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • Anti-PD-1/LAG3 bispecific antibodies
    Patent number: 11072658
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 27, 2021
    Assignees: MERCK SHARP & DOHME CORP., ZYMEWORKS, INC.
    Inventors: Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying, Eric Escobar Cabrera, Genevieve Desjardins
  • Anti-TNF? binding compounds and uses thereof
    Patent number: 10947305
    Abstract: The present invention is directed to novel Anti-TNF? antibody binding compounds and methods of using the same. Anti-TNF? antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNF? antibody binding compound. The invention further provides the use of an Anti-TNF? antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: March 16, 2021
    Assignee: Full Spectrum Genetics, Inc.
    Inventors: Robert DuBridge, Veronica Juan
  • ANTI-PD-1 ANTIBODIES
    Publication number: 20210032342
    Abstract: The present invention relates to anti-PD-1 antibodies and antigen-binding fragments, and use of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 4, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20210017276
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: July 27, 2020
    Publication date: January 21, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M.G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • Anti-B7H3 binding compounds and uses thereof
    Patent number: 10865245
    Abstract: The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: December 15, 2020
    Assignee: Full Spectrum Genetics, Inc.
    Inventors: Robert DuBridge, Veronica Juan
  • Anti-TIGIT antibodies
    Patent number: 10766957
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: September 8, 2020
    Assignee: MERCK SHARP & DOHME CORP
    Inventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • ANTI-CD27 ANTIBODIES
    Publication number: 20200131272
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Anti-CD27 antibodies
    Patent number: 10556957
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: February 11, 2020
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B. V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise